ADVA adds encryption to flagship 10G edge device
ADVA (FSE: ADV) today launched its FSP 150-XG118Pro (CSH), addressing urgent enterprise demand for high-bandwidth connectivity with robust security. The new member of the ADVA FSP 150 programmable demarcation and edge compute portfolio supports 10Gbit/s MEF 3.0 Carrier Ethernet and IP services, provides precise synchronization capabilities and now features hardware-based encryption. With its comprehensive MACsec security, the ADVA FSP 150-XG118Pro (CSH) enables business data to pass safely and seamlessly across untrusted public networks and empowers communication service providers (CSPs) to offer fully encrypted bandwidth services. What’s more, like ADVA’s FSP 3000 transport solution, the ADVA FSP 150-XG118Pro (CSH) is ready to run post-quantum cryptographic (PQC) algorithms.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005059/en/
ADVA’s new FSP 150 will prove key for businesses seeking ultimate security for high-capacity Carrier Ethernet services (Photo: Business Wire)
“Our FSP 150-XG118Pro (CSH) provides a simple and affordable route to high-capacity Carrier Ethernet connectivity with the highest levels of data protection. Unique in our industry, this compact and cost-efficient device combines demarcation, edge compute, synchronization and encryption,” said James Buchanan, GM, Edge Cloud, ADVA. “No other single solution offers all the features of our FSP 150-XG118Pro (CSH). Straight out of the box, it delivers data encryption compliant with the strictest standards in the industry, including FIPS 140-3. Our FSP 150-XG118Pro (CSH) has multi-layer demarcation capabilities as well as precise synchronization delivery. What’s more, its edge computing capabilities and open SDN control make it a key component for industrial IoT applications.”
The ADVA FSP 150-XG118Pro (CSH) combines 10Gbit/s MEF 3.0 Carrier Ethernet and IP service demarcation and aggregation with a rich set of programmability, synchronization and security features. For the first time, CSPs and businesses can deploy a compact and power-efficient solution with next-generation synchronization delivery, NFV-hosting capabilities and robust data protection. The FSP 150-XG118Pro (CSH) features precise clock technology based on Synchronous Ethernet and hardware processing of IEEE 1588 timestamps. Its fully open architecture supports ADVA’s Ensemble Connector and other virtual network function infrastructure. And, based on an enhanced version of MACsec able to encrypt across multiple domains and service provider networks, it provides end-to-end security across MEF Layer 2 cloud networks.
“Our FSP 150-XG118Pro (CSH) supports a smooth and simple transition from 1Gbit/s to 10Gbit/s services while meeting the very highest security requirements. Now there’s a simple and affordable way to achieve the safe and assured connectivity that businesses need for peace of mind and compliance with stringent regulations. The solutions also enables CSPs to roll out tailored encryption-as-a-service offerings,” commented Eli Angel, VP, product line management, ADVA. “Our FSP 150-XG118Pro (CSH) shares the same security framework as our optical products. Its cryptographic techniques, including dynamic key exchange and hardware tamper protection, ensure the safety of the most sensitive data. And, like our FSP 3000, it’s ready to support quantum-safe key exchange via a simple software upgrade.”
Watch this video for more information on the new FSP 150-XG118Pro (CSH): https://youtu.be/efdEFASaue8.
Further details are also available in these slides: https://adva.li/fsp-150-xg118pro-csh-slides.
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
ADVA Optical Networking SE, Munich, Germany
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
t +44 1904 699 358
t +49 89 890 665 854
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Successfully Prices EUR 150 Million Tap of 2026 Eurobond22.6.2021 18:46:00 CEST | Press release
SES S.A. announced today the successful launch and pricing of a tap of its 1.625% Notes due 22 March 2026 in which it has agreed to sell incremental senior unsecured fixed rate notes for a total amount of EUR 150 million. The new notes were priced at 106.665% of their nominal value representing a credit spread of 47bps and a yield-to-maturity of 0.207%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210622005953/en/ SES Successfully Prices EUR 150 Million Tap of 2026 Eurobond (Photo: Business Wire) SES is rated Baa2 by Moody’s (with negative outlook) and BBB- by Standard & Poor’s (with stable outlook). Proceeds of the issuance will be used for general corporate purposes. BBVA, Deutsche Bank and IMI Intesa Sanpaolo acted as Joint Bookrunners. The settlement is scheduled for 29 June 2021 and application has been made for the notes to be listed on the Luxembourg Stock Exchange. The securities were placed with a broad range of i
Safic-Alcan Extends Its Distribution Agreement With PMC Organometallix to the African Continent22.6.2021 18:35:00 CEST | Press release
Safic-Alcan, a global specialty chemicals distributor, is pleased to announce the extension of its distribution agreement with PMC Organometallix Inc. to the African continent. PMC Organometallix, Inc., a wholly owned subsidiary of PMC Group, N.A., Inc. has expanded its distribution agreement with Safic-Alcan to include the African continent. Effective immediately, Safic-Alcan will serve as an authorized distributor of PMC Organometallix’s FASCAT® catalysts and fine chemicals. FASCAT® catalysts are inorganic and organometallic tin compounds providing optimal conversion and curing characteristics - making these organometallic materials essential in a wide variety of applications. FASCAT® catalysts are used in the manufacture of synthetic lubricants, monomeric and polymeric ester synthesis, automotive e-coat, crosslinking of siloxanes, urethanes and chemical intermediates. “Building on our successful partnership with Safic-Alcan in continental Europe, we are pleased to extend our collabo
In Celebration of World Rainforest Day, 33 Qualified Teams and 9 Judges Announced in $10M XPRIZE Competition to Improve Understandings and Preservation of the Planet’s Rainforests22.6.2021 18:24:00 CEST | Press release
XPRIZE, the global leader in designing and operating incentive competitions to solve humanity’s grand challenges, officially announced today the teams moving forward in the $10M XPRIZE Rainforest aimed at improving our understanding of the rainforest ecosystem. Sponsored by Alana Foundation, the five-year XPRIZE Rainforest is a call-to-action to help save rainforests through the development of transformative, scalable, and affordable technology to autonomously survey and monitor biodiversity in real-time, leading to insights that communicate the health, well-being, and value of standing tropical rainforests. XPRIZE Rainforest is co-developing an inclusive framework throughout all stages of the competition that ensures competing teams co-design and co-create solutions with Indigenous Peoples and local communities as key stakeholders and not just beneficiaries. These 33 teams will now leverage existing and emerging technologies, such as robotics, remote sensing, data analysis, artificial
BourseInside, The New Media Platform That Finds Attractive Investments for Curious Investors22.6.2021 17:08:00 CEST | Press release
On the stock market, small caps continue to outperform. Since 1926, they have posted a performance of 12.1% per year, in contrast to 9.7% for large caps. And yet these so-called "small stocks" have been largely ignored by the stock market. They are rarely covered by analysts, shunned by the mainstream stock-market press and neglected by funds. Nevertheless, they are of great interest to investors, in particular those who have recently taken to investing in the stock market in order to grow their savings (16% increase in investors in 2020). For half of these newcomers, investing in the stock market gives them the opportunity to support the French economy by supporting the growth of our future champions and to channel their savings into a more sustainable and fairer model. In order to further strengthen this link between the French people and the development of our national companies, we decided to create BourseInside, the first web/TV/newsletter media platform, fully dedicated to listed
DARZALEX®▼ (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma22.6.2021 16:31:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the European Commission (EC) has granted marketing authorisation for the expanded use of DARZALEX®▼ (daratumumab) subcutaneous (SC) formulation in two new indications. The first authorisation of these new indications is for the use of daratumumab SC in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adults with newly diagnosed systemic light chain (AL) amyloidosis. This approval makes this daratumumab-based regimen the first approved therapy for AL amyloidosis in Europe. The second authorisation is for the use of daratumumab SC in combination with pomalidomide and dexamethasone (D-Pd) for the treatment of adults with multiple myeloma (MM) who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor, and have
PPG Introduces Digital Color-Matching Device for Commercial Vehicles22.6.2021 15:02:00 CEST | Press release
PPG (NYSE: PPG) today announced the introduction of its ColorReader portable digital device, which will enable customers in the commercial vehicle sector to quickly and precisely match colors to the PPG DELFLEET ONE® color palette and international standard colors. ColorReader is a BLUETOOTH®-connected device that works with a dedicated app. Available for iOS and Android tablets and smartphones, the device provides a highly accurate color match in just a few seconds. “All users have to do is download the ColorReader app, connect with their smartphone or tablet, and place ColorReader on the painted surface to scan,” said Jo Thompson, PPG color marketing manager, automotive refinish, Europe, Middle East and Africa. “ColorReader also offers a smart solution when a smartphone or tablet is not available by instantly displaying the three closest matching colors on its built-in display after scanning.” PPG recently launched ColorReader in Europe, the Middle East and Africa, and has received a
Personalis Announces NeXT Level Biomarkers Symposium22.6.2021 15:01:00 CEST | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced its inaugural event, NeXT Level Biomarkers Symposium, which will showcase novel research into emerging biomarkers using the Personalis NeXT Platform™. This event will detail the latest research from Personalis as well as a case study done in collaboration with the Parker Institute for Cancer Immunotherapy. Presentations from Personalis will focus on recently published research into HLA loss of heterozygosity, neoantigen prediction, as well as Personalis’ novel composite biomarker, the Neoantigen Presentation Score (NEOPS™). In addition, Dr. Theresa LaVallee will be presenting findings from the PRINCE trial based on data developed and analyzed in collaboration with Personalis. The agenda for NeXT Level Biomarkers Symposium will cover: Biomarker Discovery with ImmunoID NeXT Platform® Exploring HLA LOH with the DASH (Deletion of Allele-Specific HLAs) Algorithm Neoantigen Binding Prediction and Bioma